申请人:——
公开号:US20040198980A1
公开(公告)日:2004-10-07
The present invention includes novel retinoid compounds that have selectivity as RXR agonists on one or more isoforms of RXR, currently, RXR&agr;, RXR&bgr;, or RXR&ggr;. The present compounds, and pharmaceutical compositions incorporating these compounds, therefore, are effective in treating conditions mediated by RXRs. Among other physiological responses, the compounds of the present invention reduce blood glucose and maintain body weight, and, thus, are useful for the treatment of diabetes (NIDDIM) and obesity.
本发明涵盖了新型视黄醇化合物,其在RXR的一个或多个亚型上具有选择性作为RXR激动剂,目前包括RXRα、RXRβ或RXRγ。因此,本化合物及包含这些化合物的药物组合物在治疗由RXR介导的疾病方面是有效的。除其他生理反应外,本发明的化合物可降低血糖并维持体重,因此对于治疗糖尿病(NIDDIM)和肥胖症是有用的。